These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17162737)

  • 1. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.
    Arya V; Coowanitwong I; Brugos B; Kim WS; Singh R; Hochhaus G
    J Drug Target; 2006 Dec; 14(10):680-6. PubMed ID: 17162737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics.
    Coowanitwong I; Arya V; Patel G; Kim WS; Craciun V; Rocca JR; Singh R; Hochhaus G
    J Pharm Pharmacol; 2007 Nov; 59(11):1473-84. PubMed ID: 17976257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interest of cyclodextrins in spray-dried microparticles formulation for sustained pulmonary delivery of budesonide.
    Dufour G; Bigazzi W; Wong N; Boschini F; de Tullio P; Piel G; Cataldo D; Evrard B
    Int J Pharm; 2015 Nov; 495(2):869-78. PubMed ID: 26410753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
    Bassler D
    Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation.
    Fu TT; Zhao Y; Yang FF; Wen H; Liu CY; Liao YH
    Int J Pharm; 2018 Oct; 549(1-2):21-30. PubMed ID: 30048776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of budesonide microparticles using spray-drying technology for pulmonary administration: design, characterization, in vitro evaluation, and in vivo efficacy study.
    Naikwade SR; Bajaj AN; Gurav P; Gatne MM; Singh Soni P
    AAPS PharmSciTech; 2009; 10(3):993-1012. PubMed ID: 19649711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
    Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
    J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
    Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
    Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles.
    Taylor MK; Hickey AJ; VanOort M
    Pharm Dev Technol; 2006; 11(3):321-36. PubMed ID: 16895843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coated particle assemblies for the concomitant pulmonary administration of budesonide and salbutamol sulphate.
    Raula J; Rahikkala A; Halkola T; Pessi J; Peltonen L; Hirvonen J; Järvinen K; Laaksonen T; Kauppinen EI
    Int J Pharm; 2013 Jan; 441(1-2):248-54. PubMed ID: 23200957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Assessment of Pulmonary Targeting of Inhaled Corticosteroids Using Ex Vivo Receptor Binding Studies.
    Shao J; Talton J; Wang Y; Winner L; Hochhaus G
    AAPS J; 2020 Jan; 22(2):39. PubMed ID: 32002694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.
    Eriksson J; Thörn H; Sjögren E; Holmstén L; Rubin K; Lennernäs H
    Mol Pharm; 2019 Jul; 16(7):3053-3064. PubMed ID: 31136181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.
    Sahib MN; Darwis Y; Peh KK; Abdulameer SA; Tan YT
    Int J Nanomedicine; 2011; 6():2351-66. PubMed ID: 22072872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding.
    Wu K; Blomgren AL; Ekholm K; Weber B; Edsbaecker S; Hochhaus G
    Drug Metab Dispos; 2009 Jul; 37(7):1421-6. PubMed ID: 19364829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model.
    Bandi N; Ayalasomayajula SP; Dhanda DS; Iwakawa J; Cheng PW; Kompella UB
    J Pharm Pharmacol; 2005 Jul; 57(7):851-60. PubMed ID: 15969944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
    Bur M; Huwer H; Muys L; Lehr CM
    J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects.
    Harrison TW; Tattersfield AE
    Thorax; 2003 Mar; 58(3):258-60. PubMed ID: 12612308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficiency of budesonide nebulization using surface-active agents.
    Bouwman AM; Heijstra MP; Schaefer NC; Duiverman EJ; Lesouëf PN; Devadason SG
    Drug Deliv; 2006; 13(5):357-63. PubMed ID: 16877311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.
    Bhagwat S; Schilling U; Chen MJ; Wei X; Delvadia R; Absar M; Saluja B; Hochhaus G
    Pharm Res; 2017 Dec; 34(12):2541-2556. PubMed ID: 28799097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocluster budesonide formulations enhance drug delivery through endotracheal tubes.
    Pornputtapitak W; El-Gendy N; Berkland C
    J Pharm Sci; 2012 Mar; 101(3):1063-72. PubMed ID: 22095757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.